QG
QGEN.US Qiagen NV
- Market cap
- USD 10.3B
- P/E
- 26.9x
- P/B
- 2.96x
- ROE
- 10.6%
- Dividend yield
- 0.53%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is QGEN.US undervalued?
Graham numberQGEN.US trades 88.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Qiagen NV fundamental analysis
No fundamental analysis for Qiagen NV yet.
Qiagen NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components fo…
Full company profileQiagen NV financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Qiagen NV annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.34B | 1.42B | 1.50B | 1.53B | 1.87B | 2.25B | 2.14B | 1.97B | 1.98B | 2.09B | 2.10B |
| Gross Profit | 845M | 923M | 1.00B | 1.01B | 1.23B | 1.45B | 1.38B | 1.23B | 967M | 1.29B | 1.34B |
| Operating Income | 98.8M | 153M | 267M | -26.1M | 386M | 630M | 531M | 410M | 97.7M | 520M | 534M |
| EBITDA | 309M | 381M | 499M | 228M | 716M | 895M | 779M | 689M | 368M | 717M | 716M |
| Net Income | 80.4M | 40.4M | 190M | -41.5M | 359M | 513M | 423M | 341M | 83.6M | 425M | 369M |
| EPS | 0.35 | 0.17 | 0.82 | -0.19 | 1.58 | 2.28 | 1.90 | 1.57 | 0.38 | 2.04 | 1.78 |
| Balance Sheet | |||||||||||
| Total Assets | 4.31B | 5.04B | 5.75B | 5.24B | 5.87B | 6.15B | 6.29B | 6.12B | 5.69B | 6.30B | 5.94B |
| Total Liabilities | 1.70B | 2.50B | 3.11B | 2.70B | 3.07B | 3.05B | 2.82B | 2.31B | 2.12B | 2.52B | 2.47B |
| Shareholders' Equity | 2.61B | 2.54B | 2.63B | 2.54B | 2.80B | 3.10B | 3.47B | 3.81B | 3.57B | 3.78B | 3.47B |
| Cash & Short-term Investments | 532M | 1.02B | 1.42B | 753M | 715M | 1.07B | 1.42B | 1.06B | 1.15B | 1.10B | 830M |
| Total Debt | 1.07B | 1.76B | 2.17B | 1.73B | 1.95B | 2.12B | 2.03B | 1.69B | 1.61B | 1.65B | 1.64B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 342M | 287M | 359M | 331M | 492M | 639M | 715M | 459M | 674M | 654M | 596M |
| Capital Expenditure | 93.9M | 124M | 151M | 275M | 304M | 207M | 149M | 163M | 167M | 201M | 173M |
| Free Cash Flow | 248M | 162M | 209M | 56.0M | 188M | 432M | 566M | 297M | 506M | 453M | 423M |
| Ratios | |||||||||||
| ROE | 3.1% | 1.6% | 7.2% | -1.6% | 12.8% | 16.6% | 12.2% | 9.0% | 2.3% | 11.2% | 10.6% |
| ROA | 1.9% | 0.8% | 3.3% | -0.8% | 6.1% | 8.3% | 6.7% | 5.6% | 1.5% | 6.7% | 6.2% |
| Net Profit Margin | 6.0% | 2.8% | 12.7% | -2.7% | 19.2% | 22.8% | 19.8% | 17.4% | 4.2% | 20.3% | 17.6% |
| Debt to Equity | 0.41x | 0.69x | 0.83x | 0.68x | 0.70x | 0.68x | 0.58x | 0.44x | 0.45x | 0.44x | 0.47x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Qiagen NV dividends
- Dividend yield
- 0.53%
- Forward dividend
- 0.35 USD
- Payout ratio
- 12.8%
- Ex-dividend date
- Jul 7, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 54.2M | 0.26 | 12.8% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 25.4M | 0.11 | 6.0% |
| 2021 | - | - | - |
| 2020 | USD 622M | 2.74 | 173.2% |
| 2019 | - | - | - |
| 2018 | USD 567M | 2.43 | 298.0% |
| 2017 | USD 770M | 3.30 | 1,905.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 962:1000 on Jan 25, 2017.
Who owns Qiagen NV
- Insiders 0.48%
- Institutions 75.88%
- Public & others 23.64%
- Shares outstanding 206M
- Free float 205M
Top funds holding QGEN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Health Care Inv | 6.95M | 3.36% | +6.62% | Sep 2026 |
| MFS International Equity R6 | 4.00M | 1.94% | -2.25% | Sep 2026 |
| T. Rowe Price International Stock | 3.04M | 1.47% | -7.44% | Sep 2026 |
| Vanguard Total Intl Stock Index Inv | 3.04M | 1.47% | -0.32% | Sep 2026 |
| DekaFonds CF | 2.55M | 1.23% | +50.91% | Jun 2026 |
| MFS Research International I | 2.47M | 1.20% | -2.24% | Sep 2026 |
| Vanguard Developed Markets Index Admiral | 2.01M | 0.97% | -0.04% | Sep 2026 |
| BlackRock Global Equity Mkt Netrl Instl | 1.80M | 0.87% | +2.90% | Aug 2026 |
| Principal International Equity Inst | 1.77M | 0.86% | 0.00% | Sep 2026 |
| Folksam LO Världen | 1.70M | 0.83% | 0.00% | Oct 2026 |
| iShares Core MSCI EAFE ETF | 1.54M | 0.75% | 0.00% | Oct 2026 |
| Goldman Sachs Intl Sm Cp Insghts Instl | 1.45M | 0.70% | 0.00% | Jul 2026 |
| Vanguard Explorer Inv | 1.37M | 0.66% | +24.48% | Sep 2026 |
| T. Rowe Price All-Cap Opportunities Fund | 1.22M | 0.59% | 0.00% | Sep 2026 |
| Victory Sycamore Small Company Opp R | 1.12M | 0.54% | +11.44% | Sep 2026 |
| iShares TecDAX® ETF (DE) | 1.03M | 0.50% | 0.00% | Oct 2026 |
| iShares Core DAX® ETF (DE) Acc | 1.02M | 0.49% | -0.06% | Oct 2026 |
| Fidelity SAI Intl Low Volatil Idx | 1.02M | 0.49% | +2.53% | Sep 2026 |
| DFA International Core Equity 2 I | 1.01M | 0.49% | +5.05% | Sep 2026 |
| iShares Russell Mid-Cap ETF | 873K | 0.42% | -0.06% | Oct 2026 |
Top institutions holding QGEN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Wellington Management Company LLP | 12.4M | 6.01% | -13.63% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 11.4M | 5.50% | +34.70% | Jun 2026 |
| Principal Financial Group Inc | 8.40M | 4.07% | +26.27% | Sep 2026 |
| Vanguard Capital Management, LLC | 6.21M | 3.01% | +1.70% | Jun 2026 |
| BlackRock Inc | 5.91M | 2.86% | +12.48% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 5.04M | 2.44% | +20.32% | Jun 2026 |
| Earnest Partners LLC | 4.65M | 2.25% | +1.72% | Sep 2026 |
| The Goldman Sachs Group Inc | 4.44M | 2.15% | +219.38% | Jun 2026 |
| NORGES BANK | 4.33M | 2.09% | +24.64% | Jun 2026 |
| Millennium Management LLC | 3.85M | 1.86% | +543.25% | Jun 2026 |
| Amundi | 3.68M | 1.78% | -22.58% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 3.49M | 1.69% | +341.96% | Jun 2026 |
| UBS Group AG | 3.42M | 1.66% | +139.39% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 3.31M | 1.60% | +20.07% | Sep 2026 |
| Bank of America Corp | 3.00M | 1.45% | -7.68% | Jun 2026 |
| Fivespan Partners, LP | 2.69M | 1.30% | 0.00% | Jun 2026 |
| SEI Investments Co | 2.35M | 1.14% | +33.20% | Jun 2026 |
| Helikon Investments Ltd | 2.29M | 1.11% | -25.72% | Sep 2026 |
| Allspring Global Investments Holdings, LLC | 2.22M | 1.08% | -10.34% | Jun 2026 |
| Deutsche Bank AG | 2.19M | 1.06% | -60.98% | Jun 2026 |
Qiagen NV company profile
- Company name
- Qiagen NV
- Ticker
- QGEN.US
- ISIN
- NL0015002SN0
- Exchange
- USA Stocks
- Listed since
- Jun 28, 1996
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 5,400
- Fiscal year end
- December
- Address
- Hulsterweg 82, Venlo, Netherlands, 5912 PL
- Phone
- 31 77 355 6600
- Website
- qiagen.com
About Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Qiagen NV management
10- Dr. Roland SackersCFO, MD & Member of Management Board · born 1968
- Mr. Jonathan M. PrattCEO & Member of Management Board · born 1970
- Mr. Antonio SantosSenior VP & Head of Global Operations
- Mr. Daniel Wendorff CEFA, CIIAVP & Head of Investor Relations
- Mr. John GilardiVP & Head of Corporate Communications
- Ms. Stephany FosterSenior VP & Head of Human Resources · born 1979
- Dr. Thomas SchweinsSenior Vice President of Life Science Business Area
- Dr. Thomas TheuringerSenior Director & Head of External Communications
- Mr. Jean-Pascal ViolaSenior VP & Head of Corporate Strategy and Business Development
- Mr. Nitin SoodSenior VP & Head of Product Portfolio & Innovation · born 1973